

Original Research

Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial



Pascal Hammel ^{a,*}, Portales Fabienne ^b, Laurent Mineur ^c, Jean-Philippe Metges ^d, Thierry Andre ^e, Christelle De La Fouchardiere ^f, Christophe Louvet ^g, Farid El Hajbi ^h, Roger Faroux ⁱ, Rosine Guimbaud ^j, David Tougeron ^k, Olivier Bouche ¹, Thierry Lecomte ^m, Christine Rebischung ⁿ, Christophe Tournigand ^o, Jerome Cros ^p, Richard Kay ^q, Adam Hamm ^r, Anu Gupta ^s, Jean-Baptiste Bachet ^{t,1}, Iman El Hariry ^{s,1}

^a Digestive and Medical Oncology Unit, Hôpital Beaujon, Assistance Publique – Hôpitaux de Paris, University Denis Diderot Paris VII, 92110 Clichy, France

- ^b Parc Euromedecine, 208 Rue Des Apothicaires, 34070 Montpellier, France
- ^c Institut Sainte Catherine, Gastrointestinal and Liver Cancer Unit, Chemin de Baigne Pieds, 84000 Avignon, France
- ^d CHRU de Brest Hôpital Morvan, 2 Avenue Foch, 29609 Brest, France
- ^e Hôpital Saint-Antoine, 184 Rue du Faubourg Saint-Antoine, 75012 Paris, and Sorbonne Universités, France
- f Medical Oncology Department, Centre Leon Berard, Lyon, France
- ^g Department of Medical Oncology, Institut Mutualiste Montsouris, 42 Boulevard Jourdan, 75014 Paris, France
- ^h Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France
- ⁱ Les Oudairies, Hospital La Roche-Sur-Yon, Boulevard Stephane Moreau, 85000 La Roche Sur Yon, France
- ^j Institut Universitaire du Cancer, Avenue Hubert Curien, 31100 Toulouse, France
- ^k Gastroenterology Department and Medical Oncology Department, Poitiers University Hospital, Faculty of Medicine of Poitiers, 86000 Poitiers, France
- ¹ Service Oncologie Digestive, CHU Reims, Avenue Général Koenig, 51092 Reims Cede, France
- ^m Department of Hepatogastroenterology and Digestive Oncology, CHU de Tours, 37044 Tours Cedex, France
- ⁿ Groupe Hospitalier Mutualiste de Grenoble, 8 Rue Docteur Calmette, 38100 Grenoble, France
- ° Service d'Oncologie médicale, Hôpital Henri Mondor, AP-HP, Université Paris-Est, 94010 Créteil, France
- ^p Beaujon University Hospital, Department of Pathology-INSERM U1149, 100 Bvd Gal Lerclerc, 92110 Clichy, France
- ^q RK Statistics Ltd, St Giles View, Main Street, Great Longstone, Bakewell, DE45 1TZ, UK
- r Cytel Inc., 675 Massachusetts Ave Cambridge, MA 02139, USA
- ^s ERYTECH, One Main Street, Suite 1150, Cambridge, MA 02142, USA

^t Sorbonne Universités, UPMC Université, Gastroenterology and Digestive Oncology Department, Pitié Salpêtrière Hospital, 75013 Paris, France

- * Corresponding author: Digestive and Medical Oncology Unit, Hôpital Beaujon, Assistance Publique Hôpitaux de Paris, University Denis Diderot Paris VII, 92110 Clichy, France.
 - E-mail address: pascal.hammel@aphp.fr (P. Hammel).
- ¹ JBB and IEH are joint senior co-authors.

https://doi.org/10.1016/j.ejca.2019.10.020

^{0959-8049/© 2019} The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Received 24 July 2019; received in revised form 9 October 2019; accepted 13 October 2019 Available online 21 November 2019

KEYWORDS Erythrocyte; Pancreatic adenocarcinoma; Survival; Asparaginase; Asparagine synthetase	Abstract <i>Purpose:</i> This Phase IIb (NCT02195180) open-label study evaluated erythrocyte encapsulated asparaginase (eryaspase) in combination with chemotherapy in second-line advanced pancreatic adenocarcinoma. <i>Methods:</i> Eligible patients were randomized 2:1 to either eryaspase in combination with gem citabine or mFOLFOX6 (eryaspase arm), or to gemcitabine or mFOLFOX6 alone (contro arm). Co-primary endpoints were overall survival (OS) and progression-free survival (PFS in patients with low asparagine synthetase (ASNS) expression. Secondary endpoints included OS and PFS in the entire population. <i>Results:</i> 141 patients were randomized (eryaspase arm, n = 95; control arm, n = 46). Median OS and PFS in patients with low ASNS expression were 6.2 months (95% CI, 5.1–8.8) in the eryaspase arm versus 4.9 months (3.1–7.1) in the control arm (HR, 0.63; 95% CI, 0.39–1.01 $P = 0.056$) and 2.0 months (95% CI, 1.8–3.4) in the eryaspase arm versus 1.8 months (1.4–3.8) in the control arm (HR, 0.67; 95% CI, 0.40–1.12; $P = 0.127$), respectively. In the entire population, median OS and PFS for the eryaspase arm versus 1.6 months (HR, 0.56; 95% CI, 0.37–0.84; $P = 0.005$), respectively. The combination of eryaspase and chemotherapy was wel tolerated. The most frequent Grade 3/4 adverse events in the eryaspase arm (n = 93) were gamma-glutamyltransferase increase (16 [17.2%]), neutropenia (12 [12.9%]), and physica health deterioration (12 [12.9%]). <i>Conclusion:</i> Eryaspase in combination with chemotherapy is associated with improvements in OS and PFS, irrespective of ASNS expression in second-line advanced pancreatic adenocarcin noma. A Phase III trial is underway.
	© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Pancreatic adenocarcinoma is a leading cause of cancerrelated deaths in the Western world and is of increasing incidence [1]. Despite the introduction of new agents, prognosis remains generally poor with a 5-year survival of less than 5% [1]. First-line chemotherapy for metastatic disease is still primarily oxaliplatin and folinic acid with 5-fluorouracil (5-FU) or gemcitabine with nabpaclitaxel [2,3]. Although 40–50% patients failing on first-line therapy are suitable for second-line treatment, there is a lack of consensus on optimal therapy for these patients [1]. Although gemcitabine after first-line oxaliplatin is an option, outcomes are suboptimal with disease control achieved in only one in five patients [4].

An important feature of pancreatic adenocarcinoma is the high prevalence of KRAS mutations, which occur in 90% of patients, and result in the constitutive activation of RAF/MEK/ERK and PIK3/AKT-mTOR pathways [5]. Constitutive KRAS signalling is associated with the dysregulation of metabolic pathways leading to addictions to metabolites, such as glutamine and asparagine, used by non-canonical metabolic pathways [5,6]. Indeed, glutamine deprivation and/or inhibition of enzymes downstream of KRAS results in suppression of pancreatic adenocarcinoma cell growth [9]. Thus, modulation of glutamine and asparagine levels may represent a critical vulnerability of these cells [6,7].

Cellular synthesis of asparagine from aspartate and glutamine is catalysed by asparagine synthetase (ASNS). Resistance to asparaginase (ASNase) treatment in acute lymphoblastic leukaemia (ALL) has been associated with changes in ASNS expression [8]. As pancreatic tumours are notoriously hypovascular and enhanced ASNS expression is involved in adaptation responses to hypoxia and glucose deprivation, it is hypothesized that ASNS expression may be a predictive factor for ASNase susceptibility in pancreatic carcinomas [9].

Although ASNase is a key component of chemotherapy for ALL, clinical studies in solid tumours have been limited by their narrow therapeutic index and associated toxicities. A novel approach to delivering ASNase at therapeutic doses with reduced propensity for toxicities is from encapsulation of ASNase within erythrocytes (eryaspase) through a proprietary process. The RBCs used for the production of eryaspase are leukoreduced packed RBC units, which are manufactured and qualified by an approved blood bank according to current approved practices in Europe and the USA, and therefore, these follow all the safety measures put in place by health authorities for the preparation of blood products for transfusion.

The encapsulated ASNase remains biologically active, with a half-life of approximately 2 weeks. A Phase I study of single-agent eryaspase in metastatic pancreatic adenocarcinoma showed it to be well tolerated, with a recommendation for a Phase II eryaspase dose of 100 U/Kg [10].

This open-label, multicenter, randomized, Phase IIb trial assessed the efficacy and safety of eryaspase as second-line therapy in combination with chemotherapy in patients with advanced pancreatic adenocarcinoma.

2. Methods

2.1. Study design

This multicenter, open-label, randomized, Phase IIb trial, sponsored by ERYtech Pharma, was conducted at 16 centres in France under the auspices of the GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie). The trial was conducted in accordance with the protocol and principles of the International Conference of Harmonization Good Clinical Practices and Declaration of Helsinki and was approved by an independent ethics committee. Eligible patients were randomized in a 2:1 ratio to receive either eryaspase in combination with gemcitabine or mFOLFOX6 (ervaspase arm), or gemcitabine or mFOLFOX6 alone (control arm). Chemotherapy choice was determined by prior first-line therapy (gemcitabine or mFOLFOX6). Random assignment was stratified according to the first-line therapy. Co-primary endpoints in the study were OS and PFS in patients with low ASNS expression (ASNS 0/1+). Secondary endpoints included overall survival (OS) and progressionfree survival (PFS) in the entire population, objective response rate (ORR), disease control rate (DCR), treatment compliance, safety, and quality of life (QoL).

2.2. Patients

Eligible patients were ≥ 18 years with histologically confirmed, non-resectable, metastatic pancreatic adenocarcinoma who had progressed during, or following, the first-line therapy. They had also received one prior systemic therapy for advanced disease and had measurable disease by RECIST version 1.1 and a European Cooperative Oncology Group performance status (ECOG-PS) of 0/1. Patients were excluded for known hypersensitivity or prior exposure to any form of ASNase or presence of inadequate organ function. All patients provided written informed consent before screening.

2.3. Treatment and study assessments

In the 28-day treatment cycle, eryaspase 100 U/kg was administered by intravenous (IV) infusion on Days 3 and 17, gemcitabine 1000 mg/m² by 30-min IV perfusion on Day 1 weekly for 3 weeks, and mFOLFOX6 (oxaliplatin 85 mg/m² IV on Day 1, leucovorin 400 mg/m², 5-FU 400 mg/m² by IV bolus, and continuous IV infusion of 5-FU 2400 mg/m² by continuous IV infusion over 46 h) every 2 weeks. Dose modifications were permitted according to protocol-specified algorithms.

Locally performed radiological (magnetic resonance imaging [MRI] or computed tomography [CT] scan) tumour assessments were undertaken every 8 weeks from randomization until disease progression, initiation of a new cancer treatment, or death, according to RECIST version 1.1. These results were centrally reviewed by independent radiologists. Adverse events (AE) were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). An independent data safety monitoring board conducted interim safety assessments (when six and then 24 patients had received ervaspase with gemcitabine, and six patients had received ervaspase with mFOLFOX6). Clinical assessments (physical examination, vital signs, and ECOG-PS) were performed 4 weekly and standard laboratory assessments every 2 weeks. QoL, assessed using the European Organization for Research and Treatment of Cancer Quality-of-Life Core Questionnaire (EORTC-QLQ-C30) version 3 and the EORTC-QLQ-PAN26 was assessed at baseline, at Weeks 2 and 4 of treatment cycle 1, and at the end of each subsequent cycle.

ASNS expression was determined prior to randomization by immunohistochemistry using the automated IHC Ventana® slide staining system (BenchMark GX). In brief, paraffin-embedded slides from archival tissue samples were labelled with anti-ASNS polyclonal antibody (ref. HPA029318, Sigma-Aldrich). ASNS scoring was based on staining intensity, graded using a fourpoint scale: 0: not detected; 1: weak; 2: moderate; 3: strong.

2.4. Statistical analyses

The primary analysis population was the ASNS 0/ 1+ subgroup. Key secondary analyses were performed in all comers. The original primary endpoint was PFS at 16 weeks with sample size calculated assuming the null hypothesis H0: $P \le 25\%$ against the one-sided alternative hypothesis HA: P > 40%, in ASNS 0/1+ patients who were randomized to eryaspase. For 80% power, 62 ASNS 0/1+ patients would be required, assuming a PFS rate at 16 weeks of 40% in that arm. It was expected that between 70% and 80% of eligible patients would be ASNS 0/1+ and, to additionally incorporate a 2:1 randomization, the total sample size was predicted to be *All investigator decisions to discontinue treatment were related to clinical progression or general health status deterioration.



Fig. 1. Trial profile.

between 116 and 133. For an agent such as eryaspase that targets one or more metabolic pathways and in the absence of precedence of demonstrable clinical activity with similar agents in pancreatic cancer, it was unknown whether the disease-modifying effects could be observed early or late during the disease course. In addition, a review of literature indicated that effects could be seen in terms of either PFS or OS, or both. Therefore, the primary endpoint was amended (October 2016) with PFS and OS in the ASNS 0/1+ subgroup as co-primary endpoints. This was considered more appropriate as opposed to a landmark PFS rate at 16 weeks. Based on

discussions with clinical experts, an hazards ratio (HR) for either OS or PFS < 0.85 was to be viewed as an encouraging signal of activity. The sample size was not modified, as the focus was on the point estimates of the HRs rather than on formal statistical significance. OS was defined as the interval from randomization until death: PFS was defined as the interval from randomization until disease progression, including clinical progression, as per RECIST version 1.1, or death. Time-toevent data were summarized using the Kaplan-Meier methodology and HRs were obtained from the stratified Cox proportional hazards model, stratified by a background chemotherapy regimen. ORR and DCR were compared using а stratified Cochran-Mantel-Haenszel test. All OoL endpoints from the EORTC-OLO-C30 and EORTC-PAN26 questionnaires were summarized at baseline and for each visit, along with change from baseline. Safety analyses were based on the safety population, which included all patients who received \geq one dose of study drug. All statistical analyses were performed with SAS, version 9.2 or higher.

3. Results

3.1. Baseline

Between July 2014 and October 2016, 141 patients were randomized to the eryaspase (n = 95) or control (n = 46) arms (Fig. 1). As first-line chemotherapy had been principally fluoropyrimidine-based, 84 (88.4%) and 41 (89.1%) patients in the eryaspase and control arms, respectively, received generitabine. Demographic and baseline characteristics were generally comparable between treatment arms (Table 1).

3.2. Efficacy

Median patient follow-up was 6.1 months in the eryaspase arm and 4.7 months in the control arm. In patients with ASNS 0/1+, median OS was 6.2 months (95% CI, 5.1-8.8) in the eryaspase arm and 4.9 months (95% CI, 3.1-7.1) for the control (HR, 0.63; 95% CI, 0.39-1.01; P = 0.056) (Table 2; Fig. 2A). Median PFS in this ASNS group was 2.0 months (95% CI, 1.8-3.4) in the eryaspase arm and 1.8 months (95% CI, 1.4-3.8) for the control (HR, 0.67; 95% CI, 0.40-1.12; P = 0.127) (Table 2; Fig. 2B).

In the entire population (ASNS 0/1+ and ASNS 2+/ 3+), median OS was 6.0 months (95% CI, 4.8–6.6) and 4.4 months (95% CI, 3.0–5.0) in the eryaspase and control arms, respectively (HR, 0.60; 95% CI, 0.41–0.87; P = 0.008) (Table 2; Fig. 2C), with respective median PFS values of 2.0 months (95% CI, 1.8–3.4) and 1.6 months (95% CI, 1.4–1.8) (HR, 0.56; 95% CI, 0.37–0.84; P = 0.005) (Table 2; Fig. 2D).

Table 1

Baseline demographic and disease characteristics for the intent-to-treat population.

Status ^a	Eryaspase plus	Chemotherapy Total		
	chemotherapy	alone $(N = 46)$	(N = 141)	
	(N = 95)			
Gender, n (%)				
Male	53 (55.8)	30 (65.2)	83 (58.9)	
Female	42 (44.2)	16 (34.8)	58 (41.1)	
Age at randomization, ve	ars		· · · ·	
Mean (SD)	62.7 (10.2)	62.4 (8.7)	62.6 (9.7)	
Median	63	63	63	
Range	(37-84)	(43 - 80)	(37 - 84)	
ECOG-PS, n (%)	· · ·	· · · ·	ì í	
0	29 (31.5)	11 (25.6)	40 (29.6)	
1	63 (68.5)	32 (74.4)	95 (70.4)	
CA19-9	× /			
Mean (kU/L)	13268.7	10420.4	12,426.6	
(SD)	(40730.7)	(21448.3)	(36042.7)	
Time interval from initial	l diagnosis of adva	nced disease to		
randomization, month	IS			
Mean (SD)	10.7 (10.5)	10.7 (7.9)	10.7 (9.7)	
Median	8	9	8	
Range	(2-87)	(3-39)	(2 - 87)	
Stage at initial diagnosis	, n (%)			
I/II	15 (15.8)	8 (17.3)	23 (16.2)	
III	8 (8.4)	5 (10.9)	13 (9.2)	
IV	72 (75.8)	33 (71.7)	105 (74.5)	
Main sites of metastasis,	n (%)			
Liver	73 (77.7)	37 (80.4)	110 (78.6)	
Lung	23 (24.5)	8 (17.4)	31 (22.1)	
Peritoneum	21 (22.3)	9 (19.6)	30 (21.4)	
Number of metastatic sit	es, n (%)			
0-1	60 (63.2)	35 (76.1)	95 (67.4)	
2	30 (31.6)	9 (19.6)	39 (27.7)	
≥ 3	5 (5.3)	2 (4.3)	7 (5.0)	
ASNS scoring intensity,	95	46	141	
n (%)				
0/1+	66 (69.5)	32 (69.6)	98 (69.5)	
2+/3+	29 (30.5)	14 (30.4)	43 (30.5)	
Prior systemic therapy, n	95	46	141	
(%)				
Yes	94 (98.9) ^b	46 (100.0)	140 (99.3)	
Prior best overall response	se, n (%)			
Objective response and stable disease	63 (66.3)	30 (65.2)	93 (65.9)	
Progressive disease	30 (31.6)	16 (34.8)	46 (32 6)	
Non-evaluable	1 (1.1)	0	1 (0.7)	

ASNS, asparagine synthetase; CA19-9, cancer antigen 19-9; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; SD, standard deviation.

^a n in each summary is the number of patients with non-missing data for the category – percentages are calculated with the number of randomized patients with non-missing data in each group as denominator.

^b One patient was randomized outside the inclusion criteria.

In patients with ASNS 2+/3+, median OS was 4.8 months (95% CI, 3.4–6.8) in the eryaspase arm and 2.7 months (95% CI, 1.6–4.5) for the control (HR, 0.52; 95% CI, 0.26–1.04; P = 0.063) (Table 2; Fig. 2E), with respective median PFS values of 1.9 months (95% CI,

Table 2	
Summary of efficacy measures by population and treatme	nt group.

	Entire population		ASNS 0/1+		ASNS 2+/3+	
	$\mathbf{E} + \mathbf{CT} (\mathbf{N} = 95)$	CT (N = 46)	$\mathbf{E} + \mathbf{CT} (\mathbf{N} = 66)$	CT (N = 32)	$\mathbf{E} + \mathbf{CT} (\mathbf{N} = 29)$	CT (N = 14)
os						
Event rate, n (%)	82 (86.3)	42 (91.3)	55 (83.3)	28 (87.5)	27 (93.1)	14 (100.0)
Median OS, months	6.0	4.4	6.2	4.9	4.8	2.7
95% CI	4.8-6.6	3.0-5.0	5.1-8.8	3.1-7.1	3.4-6.8	1.6-4.5
HR	0.60		0.63		0.52	
95% CI	0.41-0.87		0.39-1.01		0.26-1.04	
р	0.008		0.056		0.063	
6-month OS, % PFS ^{a,b}	50.6	35.8	53.3	46.0	44.4	14.3
Event rate, n (%)	70 (73.7)	36 (78.3)	50 (75.8)	23 (71.9)	20 (69.0)	13 (92.9)
Median PFS, months	2.0	1.6	2.0	1.8	1.9	1.4
95% CI	1.8-3.4	1.4-1.8	1.8-3.4	1.4-3.8	1.6-3.4	1.0 - 1.6
HR	0.56		0.67		0.38	
95% CI	0.37-0.84		0.40-1.12		0.18-0.83	
р	0.005		0.127		0.015	
6-month PFS, %	17.2	2.9	20.4	4.5	9.5	0.0
Response ^{a,b}						
ORR, n (%)	12 (12.6)	3 (6.5)	10 (15.2)	3 (9.4)	2 (6.9)	0 (0.0)
95% CI	6.7-21.0	1.4-17.9	7.5-26.1	2.0-25.0	0.8-22.8	0.0-23.2
SD, n (%)	34 (35.8)	8 (17.4)	21 (31.8)	7 (21.9)	13 (44.8)	1 (7.1)
PD, n (%)	42 (44.2)	31 (67.4)	32 (48.5)	18 (56.3)	10 (34.5)	13 (92.9)
NE^{c} , n (%)	7 (7.4)	4 (8.7)	3 (4.5)	4 (12.5)	4 (13.8)	0 (0.0)
DCR ^d , n (%)95% CI	46 (48.4)	11 (23.9)	31 (47.0)	10 (31.3)	15 (51.7)	1 (7.1)
	38.0-58.9	12.6-38.8	34.6-59.7	16.1-50.0	32.5-70.6	0.2-33.9

ASNS, asparagine synthetase; CI, confidence interval; DCR, disease control rate; CT, chemotherapy; E + CT, eryaspace plus chemotherapy; HR, hazard ratio; NE, no follow-up scans; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; SD, stable disease.

^a Based on independent review.

^b Per RECIST criteria, version 1.1.

^c 4 consent withdrawal, 4 randomized but not treated, 1 fatal event, 1 target lesions unassessed, 1 treated but discontinued treatment before follow-up scans. NE was similar between investigator and independent review. ^d CR + PR + SD.

1.6–3.4) and 1.4 months (95% CI, 1.0–1.6) (HR, 0.38; 95% CI, 0.18–0.83; P = 0.015) (Table 2; Fig. 2F).

In the pre-determined subgroup analyses of OS and PFS, the eryaspase arm was favoured across all subgroups assessed; there was no evidence of heterogeneity across the population as a whole (Fig. 3).

ORR and DCR (complete response, partial response, and stable disease) results are reported in Table 2. Complete responses were exhibited in two patients receiving eryaspase (Table 2; Fig. 4).

For QoL, mean change from baseline in the global EORTC-QLQ-C30 score at Week 4 of Course 1 was -4.0 (SD, 18.4) in the eryaspase arm (n = 48) and -6.4 (SD, 16.3) in the control arm (n = 22).

3.3. Adherence to treatment

Treatment compliance was similar between groups (mean values; eryaspase 86.2% [SD, 14.8] versus control 87.5% [SD, 16.0]). Twenty (21.1%) patients in the eryaspase arm and seven (15.2%) patients in the control arm completed six treatment cycles. Exposure to chemotherapy was longer in the eryaspase arm than the control arm (Supplementary Table 1). In the eryaspase/gemcitabine group (n = 83), 65.1% patients required a

dose delay, and 27.7% a gemcitabine dose reduction. This compared with 59.0% and 17.9% patients, respectively, in the gemcitabine alone group. Of the 10 patients treated with eryaspase plus mFOLFOX6, eight required a dose delay and five required a dose reduction of at least one component of the mFOLFOX6 regimen, which was similar to that in the mFOLFOX6 alone arm.

3.4. Safety

Safety results are reported in Table 3. Overall, the incidence of AEs was generally similar between treatments. In both treatment arms, asthenia was the most frequent AE, followed by nausea. Haematological AEs were more frequent with combination therapy compared with chemotherapy alone; however, Grade 3/4 haematological AEs occurred with similar frequency between treatment arms. Discontinuations for treatment-related AEs were reported in 29% and 18.2% of patients in the eryaspase and control arms, respectively. One or more AEs with a fatal outcome were reported in 10 (10.8%) eryaspase-treated patients and in eight (18.2%) control patients (Supplementary Table 2). These fatal outcomes were not considered treatment-related in the eryaspase arm.



Fig. 2. Kaplan–Meier curves depicting OS in ASNS 0/1 + population (A); PFS in ASNS 0/1 + population (B); OS in entire population (C); PFS in entire population (D); OS in ASNS 2+/3 + population (E); PFS in ASNS 2+/3 + population (F).

4. Discussion

In this open-label, randomized, Phase IIb study of eryaspase in combination with chemotherapy for second-line treatment of advanced pancreatic adenocarcinoma, eryaspase demonstrated an encouraging signal of activity for the co-primary endpoints of OS and PFS in the ASNS 0/1+ population. In addition, eryaspase with chemotherapy significantly prolonged OS and PFS in the entire ASNS population compared with chemotherapy alone, with a 40% reduction in risk of death on average over time. In a pre-planned subgroup analyses, the effect of eryaspase on OS and PFS was maintained across all subgroups; there was no evidence of heterogeneity in the treatment effect. In addition, treatment with eryaspase led to encouraging improvements in ORR and DCR in the entire population, as well as in the ASNS 0/1+ subgroup.

To our knowledge, this study represents the largest cohort of patients treated with gemcitabine alone after fluoropyrimidine-based chemotherapy. Thus, our results are consistent with those for nanoliposomal irinotecan and also with those in the gemcitabine post-FOLFIRINOX setting [11,12].

ASNS=asparagine synthetase; CA19.9=cancer antigen 19.9; CI=confidence interval; CR=complete response; ECOG=European Cooperative Oncology Group; HR=hazard ratio; OR=objective response; PD=progressive disease; SD=stable disease.



Fig. 3. Forest plot of overall survival (A) and progression-free survival (B; independent assessment) hazard ratios in prognostic factors (intention-to-treat population).

*Patients with new tumours whose best overall response was progressive disease were assigned a value of +150% to highlight the poorest 'best outcome'.



Fig. 4. Waterfall plot of best response in tumour percentage change from baseline in the sum of longest diameter, based on independent radiological review eryaspase arm (A) and control arm (B).

This is the first study to prospectively evaluate any association between ASNS protein expression and clinical outcomes in ASNase-treated metastatic pancreatic adenocarcinoma. These results appear counterintuitive, given previous reports suggesting that low ASNS expression in lymphoblastic cells renders them susceptible to asparagine depletion, and that upregulation of ASNS mRNA/protein levels are associated with resistance to ASNase [13–15]. However, being *in vitro* studies, in which various metabolic pathway products and equilibrium conditions could be altered, these findings may not be analogous to *in vivo* results [16]. Clinically, several studies have demonstrated a lack of correlation between ASNS mRNA/protein levels and ASNase sensitivity in ALL [17,18]. It is plausible that ASNS serves as a prognostic indicator (as opposed to predictive indicator) of ASNase sensitivity in ALL or other malignancies. In pancreatic cancer cells, enhanced

Table 3

Most frequent ($\geq 10\%$ of patients in either treatment arm) adverse events, regardless of relationship to study drug.

Preferred term	Eryaspase plus chemotherapy (N = 93)		Chemotherapy $(N = 44)$	
	All grades	Grades 3/4	All grades	Grades 3/4
Patients with ≥ 1 AE	93 (100.0)	73 (78.5)	44 (100.0)	38 (86.4)
Asthenia	64 (68.8)	6 (6.5)	29 (65.9)	12 (27.3)
Nausea	58 (62.4)	4 (4.3)	26 (59.1)	1 (2.3)
Anaemia	42 (45.2)	8 (8.6)	22 (50.0)	5 (11.4)
Vomiting	41 (44.1)	4 (4.3)	15 (34.1)	2 (4.5)
Thrombocytopaenia	40 (43.0)	9 (9.7)	16 (36.4)	4 (9.1)
Abdominal pain	33 (35.5)	7 (7.5)	17 (38.6)	4 (9.1)
Diarrhoea	37 (39.8)	3 (3.2)	13 (29.5)	0 (0.0)
Decreased appetite	28 (30.1)	2 (2.2)	16 (36.4)	5 (11.4)
Pyrexia	28 (30.1)	1 (1.1)	12 (27.3)	0 (0.0)
Constipation	25 (26.9)	1 (1.1)	12 (27.3)	1 (2.3)
Neutropenia	23 (24.7)	12 (12.9)	7 (15.9)	5 (11.4)
GGT increased	18 (19.4)	16 (17.2)	11 (25.0)	11 (25.0)
Physical health deterioration	17 (18.3)	12 (12.9)	7 (15.9)	2 (4.5)
Antibody test positive	16 (17.2)	1 (1.1)	0 (0.0)	0 (0.0)
Weight decreased	15 (16.1)	1 (1.1)	9 (20.5)	0 (0.0)
Peripheral oedema	16 (17.2)	0 (0.0)	7 (15.9)	0 (0.0)
Upper abdominal pain	14 (15.1)	2 (2.2)	9 (20.5)	3 (6.8)
Stomatitis	15 (16.1)	0 (0.0)	5 (11.4)	0 (0.0)
ALT increased	14 (15.1)	6 (6.5)	2 (4.5)	2 (4.5)
Hypokalemia	13 (14.0)	4 (4.3)	3 (6.8)	1 (2.3)
Neuropathy peripheral	13 (14.0)	2 (2.2)	9 (20.5)	3 (6.8)
Fatigue	12 (12.9)	3 (3.2)	8 (18.2)	4 (9.1)
Back pain	11 (11.8)	0 (0.0)	5 (11.4)	0 (0.0)
Cough	11 (11.8)	0 (0.0)	3 (6.8)	0 (0.0)
Mucosal inflammation	11 (11.8)	0 (0.0)	3 (6.8)	1 (2.3)
Alopecia	11 (11.8)	1 (1.1)	1 (2.3)	0 (0.0)
Hyperthermia	11 (11.8)	1 (1.1)	0 (0.0)	0 (0.0)
Lymphopenia	10 (10.8)	3 (3.2)	3 (6.8)	2 (4.5)
Hyperglycemia	10 (10.8)	7 (7.5)	3 (6.8)	2 (4.5)
AST increase	10 (10.8)	3 (3.2)	1 (2.3)	1 (2.3)
Anxiety	9 (9.7)	1 (1.1)	6 (13.6)	0 (0.0)
Hypoalbuminemia	8 (8.6)	1 (1.1)	8 (18.2)	1 (2.3)
Insomnia	8 (8.6)	0 (0.0)	6 (13.6)	0 (0.0)

AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase.

ASNS expression may convey protection against apoptosis induced by glucose deprivation and cisplatin, indicating a shift in cellular metabolism [9]. Our study appears to indicate that high ASNS expression could be an indicator of poor prognosis, as reflected by the differing OS outcomes between ASNS groups. However, some caution should be applied because, in this study, ASNS testing was performed on archival tissues.

The combination of eryaspase and chemotherapy was generally well tolerated; no unexpected safety findings were reported, and eryaspase did not add substantially to the toxicity of chemotherapy.

Potential limitations of the study are from the change in the primary endpoint and no formal control of multiplicity. All analyses were planned *a priori*, and the change was made prior to data unblinding and final analyses. However, multiple sensitivity analyses suggest that the findings are robust (Supplementary Tables 3 and 4). As a proof-of-concept study, the co-primary endpoints relied on numerical values, rather than statistical significance. Consistency of the clinical effect across all subpopulations supports the external validity of these results.

In conclusion, addition of eryaspase to chemotherapy confers clinical benefit, irrespective of ASNS tumourexpression status, when used in the second-line treatment of advanced pancreatic adenocarcinoma. To our knowledge, this is the only Phase IIb study investigating ASNase in pancreatic cancer or in any other solid tumour. Furthermore, this is the only prospective study assessing the predictive value of ASNS expression. A confirmatory Phase III study will assess the OS benefit of eryaspase in combination with gemcitabine and nabpaclitaxel versus nanoliposomal irinotecan-based chemotherapy in second-line advanced pancreatic cancer.

Role of the funding source

This work was funded by ERYtech Pharma. The funding source was involved in the design, interpretation, or conduct of this evaluation, manuscript writing, and the decision to submit or publish the data. ERYtech Pharma reviewed the manuscript before journal submission. However, the authors are fully responsible for the content of this manuscript, and the views and opinions described in the publication reflect solely those of the authors.

Conflict of interest statement

PH has received personal fees from Amgen, Astra-Zeneca, Celgene, Halozyme, Merck Serono, Shire, Sanofi, Servier, and non-financial support from Astra-Zeneca, Celgene, and Halozyme. JBB has received personal fees from Amgen, Bayer, Celgene, Merck Serono, Roche, Sanofi, Servier, and non-financial support from Amgen, Merck Serono, and Roche. TA has received honoraria from Lilly, Sanofi Aventis, and Yakult. OB reports grants from Roche and Pierre Fabre and personal fees outside the submitted work from Roche, Pierre Fabre, Amgen, Bayer, Lilly, Merck, and Novartis. LM, CDLF, PF, DT, RG, AH, JC, RK, RF, CT, CL, and TL have no interests to declare. AN and IEH are employees of ERYtech Pharma.

Acknowledgements

The authors would like to thank all patients and their families participating in the trial. Medical writing support in the development of this manuscript was provided by Kris Holmes and Helen Farrington from Prescript Communications Ltd.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ejca.2019.10.020.

References

- Malvezzi Moore, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol 2017;28: 1117–23. https://doi.org/10.1093/annonc/mdx033.
- [2] Conroy T, Desseigne F, Ychou Moore, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817–25. https:// doi.org/10.1056/NEJMoa1011923.
- [3] Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore Moore, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369: 1691–703. https://doi.org/10.1056/NEJMoa1304369.
- [4] Sarabi Moore, Mais L, Oussaid N, Desseigne F, Guibert P, De La Fouchardiere C, et al. Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncol Lett 2017;13:4917–24. https:// doi.org/10.3892/ol.2017.6061.
- [5] Liu J, Ji S, Liang C, Qin Y, Jin K, Liang D, et al. Critical role of oncogenic KRAS in pancreatic cancer (review). Mol Med Rep 2016;13:4943–9. https://doi.org/10.3892/mmr.2016.5196.
- [6] Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio Moore, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013;496:101–5. https://doi.org/10.1038/nature12040.
- [7] Kawada K, Toda K, Sakai Y. Targeting metabolic reprogramming in KRAS-driven cancers. Int J Clin Oncol 2017;22:651–9. https://doi.org/10.1007/s10147-017-1156-4.
- [8] Shrivastava A, Khan AA, Khurshid Moore, Kalam MA, Jain SK, Singhal PK, et al. Recent developments in L-asparaginase discovery and its potential as anticancer agent. Crit Rev Oncol Hematol 2016;100:1–10. https://doi.org/10.1016/j.critrevonc. 2015.01.002.
- [9] Cui H, Darmanin S, Natsuisaka Moore, Kondo T, Asaka Moore, Shindoh Moore. Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from

apoptosis induced by glucose deprivation and cisplatin. Cancer Res 2007;67:3345-55. https://doi.org/10.1158/0008-5472.CAN-06-2519.

- [10] Bachet JB, Gay F, Marechal R, Galais MP, Adenis A, MsC DS, et al. Asparagine synthetase expression and phase i study with lasparaginase encapsulated in red blood cells in patients with pancreatic adenocarcinoma. Pancreas 2015;44:1141-7. https:// doi.org/10.1097/MPA.00000000000394.
- [11] Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014;32:2423–9. https://doi.org/10.1200/JCO.2013.53.6995.
- [12] Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016;387:545-7. https://doi.org/ 10.1016/S0140-6736(15)00986-1.
- [13] Su N, Pan YX, Zhou Moore, Harvey RC, Hunger SP, Kilberg MS. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr Blood Cancer 2008;50: 274–9. https://doi.org/10.1002/pbc.21213.
- [14] Appel IM, den Boer ML, Meijerink JP, Veerman AJ, Reniers NC, Pieters R. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood 2006;107:4244–9. https:// doi.org/10.1182/blood-2005-06-2597.
- [15] Hutson RG, Kitoh T, Moraga Amador DA, Cosic S, Schuster SM, Kilberg MS. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am J Physiol 1997;272(5 Pt 1):C1691–9. https://doi.org/10. 1152/ajpcell.1997.272.5.C1691.
- [16] Wagner A, Boos J. Unphysiological effects contributing to asparaginase toxicity in vitro. Am J Physiol 1998;274:C1185–6. https://doi.org/10.1152/ajpcell.1998.274.4.C1185.
- [17] Dimitriou H, Choulaki C, Perdikogianni C, Stiakaki E, Kalmanti Moore. Expression levels of ASNS in mesenchymal stromal cells in childhood acute lymphoblastic leukemia. Int J Hematol 2014;99:305–10. https://doi.org/10.1007/s12185-014-1509-y.
- [18] Hermanova I, Trka J, Starkova JS. Diverse asparagine synthetase expression in lymphoid blasts is not relevant to the sensitivity to lasparaginase. Haematologica 2010;95(9).